Philippe Aftimos, MD · @aftimosp · X·· 2 天前评分70
正文 · 原文
PANKU-Breast01 🇨🇳: dual EGFR and HER3 ADC Iza-Bren vs TPC in HR+/HER2- pre-treated MBC:
🔹 Median PFS improvement with Iza-bren: 8.2 vs 4 months (HR 0.41)
🔹 OS immature
🔸 More grade 3 AEs with Iza-bren
#ESMO26 #ESMOAmbassadors
@myESMO @PTarantinoMD @E_de_Azambuja
373 浏览 · 3 赞 · 2 转发 · 0 回复
会议摘要
LBA50按 Proffered paper 1: Breast cancer, early and advanced stage 对上
PANKU-Breast01: Randomized phase III study of izalontamab brengitecan (iza-bren) in previously treated unresectable locally advanced or metastatic (LA/M) hormone receptor-positive/HER2-negative (HR+/HER2-) breast cancer (BC)
https://esmocongress.esmo.org来源：Philippe Aftimos, MD · x.com